Evidence map›Paper›PMID 39912496›Full record

ArticleAutophagy2025

Development and validation of a sensitive sandwich ELISA against human PINK1.

Zahra Baninameh, Jens O Watzlawik, Bernardo A Bustillos, Gabriella Fiorino, Tingxiang Yan, Szymon L Lewicki, Haonan Zhang, Dennis W Dickson, Joanna Siuda, Zbigniew K Wszolek and 2 more

Abstract readValidation Study
In one paragraph

Article in Autophagy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zahra BaninamehDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Jens O WatzlawikDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Bernardo A BustillosDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Gabriella FiorinoDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Tingxiang YanDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Szymon L LewickiDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Haonan ZhangDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Joanna SiudaDepartment of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Wolfdieter SpringerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Fabienne C FieselDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-1919-9676

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER · 2019 to 2026
$120.9M
Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J · 2019 to 2023
$14.5M
Molecular mechanisms of PINK1-PRKN directed mitochondrial quality controlRF1NS085070 · NINDS · MAYO CLINIC JACKSONVILLE · PI SPRINGER, WOLFDIETER · 2019 to 2019
$2.8M
Mitochondrial Sirtuin 3 in Parkinson's diseaseR01NS110085 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J, SPRINGER, WOLFDIETER · 2019 to 2023
$2.5M
Selective autophagy in Alzheimer's disease and related dementiasR56AG062556 · NIA · MAYO CLINIC JACKSONVILLE · PI FRYER, JOHN DAVID, SPRINGER, WOLFDIETER · 2019 to 2019
$782k
NIA NIH HHS R56 AG062556NIA NIH HHS U19 AG063911NINDS NIH HHS R01 NS110085NINDS NIH HHS RF1 NS085070NINDS NIH HHS U54 NS110435
6 · The paper itself

Abstract

The ubiquitin kinase and ligase PINK1 and PRKN together label damaged mitochondria for their elimination in lysosomes by selective autophagy (mitophagy). This cytoprotective quality control pathway is genetically linked to familial Parkinson disease but is also altered during aging and in other neurodegenerative disorders. However, the molecular mechanisms of these mitophagy changes remain uncertain. In healthy mitochondria, PINK1 protein is continuously imported, cleaved, and degraded, but swiftly accumulates on damaged mitochondria, where it triggers the activation of the mitophagy pathway by phosphorylating its substrates ubiquitin and PRKN. Levels of PINK1 protein can therefore be used as a proxy for mitochondrial damage and mitophagy initiation. However, validated methodologies to sensitively detect and quantify PINK1 protein are currently not available. Here, we describe the development and thorough validation of a novel immunoassay to measure human PINK1 on the Meso Scale Discovery platform. The final assay showed excellent linearity, parallelism, and sensitivity. Even in the absence of mitochondrial stress (i.e. at basal conditions), when PINK1 protein is usually not detectable by immunoblotting, significant differences were obtained when comparing samples from patient fibroblasts or differentiated neurons with and without PINK1 expression. Of note, PINK1 protein levels were found increased in human postmortem brain with normal aging, but not in brains with Alzheimer disease, suggesting that indeed different molecular mechanisms are at play. In summary, we have developed a novel sensitive PINK1 immunoassay that will complement other efforts to decipher the roles and biomarker potential of the PINK1-PRKN mitophagy pathway in the physiological and pathological context.

Indexed as

Protein KinasesBrainEnzyme-Linked Immunosorbent AssayFibroblastsHumansMitochondriaMitophagyNeuronsParkinson DiseasePTEN-Induced Putative KinaseUbiquitin-Protein LigasesProtein KinasesPTEN-Induced Putative KinaseUbiquitin-Protein LigasesAutophagymitophagyParkinPINK1P-S65-Ububiquitin

Identifiers

PMID39912496
PMCPMC12013435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.